Categories
Change Password!
Reset Password!
Both 10 mg and 20 mg doses of Vonoprazan effectively alleviate heartburn symptoms, with benefits starting on the first day and lasting 20 weeks.
In a study issued in "Clinical Gastroenterology and Hepatology", Vonoprazan, a potassium-competitive acid blocker (P-CAB), rapidly reduced heartburn symptoms in non-erosive reflux disease (NERD) patients, with effects starting on day 1 and lasting through 20 weeks. Both 10 mg and 20 mg doses showed similar efficacy. This randomized trial involved 772 adults with frequent heartburn (≥4 days per week) and no evidence of erosive esophagitis on endoscopy.
The enrolled participants were randomly allocated to one of three groups: placebo, Vonoprazan 10 mg, or Vonoprazan 20 mg, and treated for 4 weeks. After the initial 4 weeks, those who had been receiving placebo were re-allocated to get either Vonoprazan 10 mg or 20 mg. Those who were already on Vonoprazan continued on the same dose for the 20-week extension phase.
During this period, electronic diaries were used for tracking heartburn symptoms, and the key outcome was the percentage of days without daytime or nighttime heartburn, referred to as "24-hour heartburn-free days. At the end of the 4-week period, those on placebo reported 27.7% of days as heartburn-free, when compared to 44.8% for the Vonoprazan 10 mg group and 44.4% for the Vonoprazan 20 mg group. The difference in heartburn-free days between Vonoprazan 10 mg and placebo was 17.1%, and between Vonoprazan 20 mg and placebo was 16.7%.
Remarkable improvements in heartburn-free days were observed from as early as the first day of treatment. For example, on day 1, Vonoprazan 10 mg illustrated an 8.3% difference, and the 20 mg dose portrayed an 11.6% difference as opposed to placebo. By day 2, the differences escalated to 18.1% for Vonoprazan 10 mg and 23.2% for Vonoprazan 20 mg compared to placebo.
During the 20-week extension phase, the mean/median percentage of 24-hour heartburn-free days was stable across all study groups, ranging from 61% to 63% (mean) and 76% to 79% (median) for both Vonoprazan doses. This indicates that the treatment effect persisted throughout the extended treatment period. Hence, Vonoprazan offers quick and lasting heartburn relief in NERD, maintaining efficacy over 20 weeks.
Clinical Gastroenterology and Hepatology
Vonoprazan is Efficacious for Treatment of Heartburn in Non-erosive Reflux Disease: A Randomized Trial
Loren Laine et al.
Comments (0)